CJC 1008

Drug Profile

CJC 1008

Alternative Names: CCI 1008; DAC:Dynorphin A; DAC:Opioid

Latest Information Update: 21 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ConjuChem Biotechnologies
  • Class
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Neuralgia; Postoperative pain

Most Recent Events

  • 03 Jul 2006 No development reported - Phase-II for Neuralgia in USA (unspecified route)
  • 03 Jul 2006 No development reported - Phase-II for Postoperative pain in USA (unspecified route)
  • 16 Dec 2002 ConjuChem has completed a phase II study with CJC 1008 in the prevention of pain following hysterectomy surgery
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top